Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franziska Gamma

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Gene|July 12, 2017
Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugsAurélie Delacrétaz, Adna Zdralovic, Frederik Vandenberghe, et al.
Schizophrenia Bulletin|July 15, 2025
Influence of CYP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to AripiprazoleCécile Gras, Marianna Piras, Setareh Ranjbar, et al.
Clinical Pharmacology and Therapeutics|May 12, 2025
Cytochrome P450 2D6 Poor Metabolizers and Risperidone Treatment Failure: A 1-Year Longitudinal StudyMarianna Piras, Setareh Ranjbar, Séverine Crettol, et al.
Translational Psychiatry|June 27, 2026
Psychotropic drug-induced weight gain and untargeted metabolomics: machine learning-driven results from a prospective cohort studyMarianna Piras, Gaëlle Magliocco, Setareh Ranjbar, et al.
Frontiers in Psychiatry|January 6, 2022
Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric CohortNermine Laaboub, Mehdi Gholam, Guibet Sibailly, et al.
Schizophrenia Bulletin|September 19, 2025
CYP2D6 Genotypes Do Not Affect Clozapine Levels in a Large, Multicenter Cohort: Time Has Come to Revise Food and Drug Administration's Clozapine Packet InsertGeorgios Schoretsanitis, Nermine Laaboub, Séverine Crettol, et al.
BMC Psychiatry|May 17, 2022
Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohortNermine Laaboub, Céline Dubath, Setareh Ranjbar, et al.
Molecular Psychiatry|September 17, 2025
Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response: genetic, epigenetic and clinical analysesNermine Laaboub, Frederik Vandenberghe, Nicolas Ansermot, et al.
The Lancet Regional Health. Europe|August 30, 2022
The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samplesBenjamin I Perry, Frederik Vandenberghe, Nathalia Garrido-Torres, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Gene|July 12, 2017
Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugsAurélie Delacrétaz, Adna Zdralovic, Frederik Vandenberghe, et al.
Schizophrenia Bulletin|July 15, 2025
Influence of CYP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to AripiprazoleCécile Gras, Marianna Piras, Setareh Ranjbar, et al.
Clinical Pharmacology and Therapeutics|May 12, 2025
Cytochrome P450 2D6 Poor Metabolizers and Risperidone Treatment Failure: A 1-Year Longitudinal StudyMarianna Piras, Setareh Ranjbar, Séverine Crettol, et al.
Translational Psychiatry|June 27, 2026
Psychotropic drug-induced weight gain and untargeted metabolomics: machine learning-driven results from a prospective cohort studyMarianna Piras, Gaëlle Magliocco, Setareh Ranjbar, et al.
Frontiers in Psychiatry|January 6, 2022
Associations Between High Plasma Methylxanthine Levels, Sleep Disorders and Polygenic Risk Scores of Caffeine Consumption or Sleep Duration in a Swiss Psychiatric CohortNermine Laaboub, Mehdi Gholam, Guibet Sibailly, et al.
Schizophrenia Bulletin|September 19, 2025
CYP2D6 Genotypes Do Not Affect Clozapine Levels in a Large, Multicenter Cohort: Time Has Come to Revise Food and Drug Administration's Clozapine Packet InsertGeorgios Schoretsanitis, Nermine Laaboub, Séverine Crettol, et al.
BMC Psychiatry|May 17, 2022
Insomnia disorders are associated with increased cardiometabolic disturbances and death risks from cardiovascular diseases in psychiatric patients treated with weight-gain-inducing psychotropic drugs: results from a Swiss cohortNermine Laaboub, Céline Dubath, Setareh Ranjbar, et al.
Molecular Psychiatry|September 17, 2025
Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response: genetic, epigenetic and clinical analysesNermine Laaboub, Frederik Vandenberghe, Nicolas Ansermot, et al.
The Lancet Regional Health. Europe|August 30, 2022
The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samplesBenjamin I Perry, Frederik Vandenberghe, Nathalia Garrido-Torres, et al.
Pageof 3